首頁 > 市場調查報告書 > 醫療設備

e保健醫院 IT

市場調查報告書

商品編碼

2126459

心臟衰竭診斷市場－策略分析與預測（2026-2031年）

Heart Failure Diagnostics Market - Strategic Insights and Forecasts (2026-2031)

出版日期: 2026年08月17日 | 出版商:

Knowledge Sourcing Intelligence | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計心臟衰竭診斷市場將以 9.5% 的複合年成長率成長，從 2026 年的 107.8 億美元成長到 2031 年的 243.5 億美元。

全球心臟衰竭診斷市場正經歷顯著的變革，其驅動力在於心血管疾病盛行率的上升以及向基於生物標記的綜合診斷路徑的轉變。該市場涵蓋診斷設備、臨床實驗室、影像系統、軟體平台以及旨在檢測和評估心臟衰竭的臨床服務。診斷評估包括測量循環血液中的心臟生物標記、利用影像技術評估心臟結構和功能以及持續監測疾病進展。心臟衰竭仍然是全球老年人住院的主要原因之一，而由於人口老化以及高血壓、糖尿病、肥胖和冠狀動脈疾病盛行率的上升，高危險群不斷擴大，市場需求也在不斷成長。在疾病早期，僅靠臨床實驗室往往缺乏足夠的特異性，因此需要更多地依賴生物標記檢測和先進的影像技術來進行及時診斷。監管機構和循環系統專業學會持續支持包含利鈉肽檢測和實證影像技術的標準化診斷流程。這些結構性變革正使心臟衰竭診斷成為現代循環系統醫學的重要組成部分。

市場促進因素

全球日益加重的心臟衰竭負擔

心臟衰竭是影響全球醫療保健系統的最嚴重的心血管疾病之一。這主要是由於人口老化以及高血壓、缺血性心臟病、糖尿病和肥胖症盛行率的不斷上升，導致患者群體持續成長。隨著臨床醫生努力在不可逆的心臟功能障礙發生之前識別心臟衰竭，對精準診斷方案的需求日益成長。傳統的臨床評估在疾病早期階段的準確性有限，因此越來越依賴檢查室生物標記和先進的心臟影像。醫療機構正在擴展其診斷能力，以改善早期療育並減少再入院率。這種結構性轉變加劇了對全面心臟衰竭診斷的長期需求。

擴大利鈉肽檢測的臨床應用。

利鈉肽（NAP）檢測是現代心臟衰竭診斷的基礎，因為生物標記BNP和NT-proBNP能夠客觀地反映心臟負荷和心室功能障礙。臨床指引建議對出現疑似心臟衰竭症狀的患者進行生物標記檢測，其在急診和門診循環系統的常規應用也日益增多。診斷實驗室正在擴展自動化免疫檢測平台，以應對不斷成長的檢測量，同時提高分析的一致性。生物標記解讀的標準化將有助於做出更可靠的臨床決策，並加強實證循環系統醫學的發展。

先進心臟影像診斷技術的擴展

心臟影像影像學能夠提供僅靠檢查室檢查無法獲得的心室功能、結構異常和疾病嚴重程度的重要資訊。醫療機構正加大對心臟超音波圖、心臟磁振造影、CT影像和人工智慧輔助診斷軟體的投資，以提高診斷準確性和治療方案製定效率。高解析度成像系統的日益普及，使得疾病的早期定性成為可能，同時降低了診斷的不確定性。全面的影像學能力能夠加強醫院和專科心臟中心的多學科心臟衰竭管理。

診斷平台的技術進步

診斷領域的創新不斷提升心血管診斷的分析靈敏度、工作流程自動化程度和數位化整體度。製造商們正在推出高靈敏度的生物標記檢測、攜帶式概念驗證 (PoC) 設備以及人工智慧驅動的成像解決方案，這些方案能夠在不影響臨床準確性的前提下加快診斷速度。檢查室自動化和數位化報告系統提高了營運效率，並有助於更快地做出治療決策。這些技術進步正在推動心血管診斷轉向精準醫療模式。

市場限制因素

先進心臟影像系統所需的大量資金投入限制了其在小規模醫療機構和資源匱乏地區的普及。不同醫療系統在取得專業循環系統服務和影像技術方面的差異，導致診斷服務取得不均。儘管越來越多的臨床證據支持對心臟衰竭進行全面評估，但保險對先進診斷程序的報銷額度有限，阻礙了其廣泛應用。此外，整合多種診斷方法以建立一致的臨床工作流程也存在複雜性，可能帶來營運方面的挑戰。

通過診斷測試
- 利鈉肽檢測（BNP、NT-proBNP）
- 心肌肌鈣蛋白檢測
- 心臟超音波圖
- 心電圖（ECG）
- 心臟磁振造影（心臟MRI）
- 電腦斷層掃描（CT）
- 胸部X光片
- 即時心臟衰竭檢測
透過技術
- 免疫測量
- 臨床化學分析儀
- 分子診斷
- 超音波影像設備
- 人工智慧驅動的診斷平台
最終用戶
- 醫院
- 診斷檢查室
- 循環系統診所
- 門診部
- 學術研究機構

第10章：心臟衰竭診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：心臟衰竭診斷市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthineers AG
Beckman Coulter, Inc.（Danaher Corporation）
bioMerieux SA
QuidelOrtho Corporation
Fujirebio Holdings, Inc.
Sysmex Corporation
Becton, Dickinson and Company（BD）
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Labcorp Holdings Inc.
Koninklijke Philips NV
GE HealthCare Technologies Inc.
Canon Medical Systems Corporation

第14章：心臟衰竭診斷市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009135

The Heart Failure Diagnostics Market is forecast to grow at a CAGR of 9.5%, reaching USD 24.35 billion in 2031 from USD 10.78 billion in 2026.

The global heart failure diagnostics market is undergoing a significant transformation, driven by the rising prevalence of cardiovascular disease and the shift toward integrated, biomarker-guided diagnostic pathways. This market encompasses diagnostic instruments, laboratory assays, imaging systems, software platforms, and clinical services designed to detect and evaluate heart failure. Diagnostic evaluation includes measurement of circulating cardiac biomarkers, assessment of cardiac structure and function through imaging technologies, and continuous monitoring of disease progression. Demand is increasing because heart failure remains one of the leading causes of hospitalization among older adults worldwide, while demographic aging and increasing prevalence of hypertension, diabetes, obesity, and coronary artery disease continue expanding the at-risk population. Clinical examination alone frequently lacks sufficient specificity during early disease presentation, increasing dependence on biomarker testing and advanced imaging for timely diagnosis. Regulatory agencies and professional cardiovascular societies continue supporting standardized diagnostic algorithms that incorporate natriuretic peptide testing and evidence-based imaging modalities. These structural changes position heart failure diagnostics as an essential component of modern cardiovascular care.

Market Drivers

Rising Global Burden of Heart Failure

Heart failure represents one of the most significant cardiovascular diseases affecting healthcare systems worldwide because aging populations and increasing prevalence of hypertension, ischemic heart disease, diabetes, and obesity continue expanding the patient population. Demand is increasing for accurate diagnostic solutions as clinicians seek to identify heart failure before irreversible cardiac dysfunction develops. Conventional clinical assessment provides limited certainty during early disease stages, creating greater reliance on laboratory biomarkers and advanced cardiac imaging. Healthcare providers are expanding diagnostic capacity to improve early intervention and reduce recurrent hospitalizations. This structural shift strengthens long-term demand for comprehensive heart failure diagnostics.

Increasing Clinical Adoption of Natriuretic Peptide Testing

Natriuretic peptide testing forms the cornerstone of modern heart failure diagnosis because BNP and NT-proBNP biomarkers provide objective evidence of cardiac stress and ventricular dysfunction. Clinical guidelines recommend biomarker assessment for patients presenting with symptoms suggestive of heart failure, increasing routine utilization across emergency departments and outpatient cardiology services. Diagnostic laboratories are expanding automated immunoassay platforms to accommodate higher testing volumes while improving analytical consistency. Standardized biomarker interpretation supports more confident clinical decision-making and strengthens evidence-based cardiovascular care.

Expansion of Advanced Cardiac Imaging

Cardiac imaging provides essential information regarding ventricular function, structural abnormalities, and disease severity that cannot be obtained through laboratory testing alone. Healthcare institutions are investing in echocardiography, cardiac MRI, CT imaging, and AI-assisted diagnostic software to improve diagnostic accuracy and treatment planning. Increasing availability of high-resolution imaging systems supports earlier disease characterization while reducing diagnostic uncertainty. Comprehensive imaging capabilities strengthen multidisciplinary heart failure management across hospitals and specialty cardiac centers.

Technological Advancements in Diagnostic Platforms

Diagnostic innovation continues improving analytical sensitivity, workflow automation, and digital integration across cardiovascular diagnostics. Manufacturers are introducing highly sensitive biomarker assays, portable point-of-care testing devices, and artificial intelligence-enabled imaging solutions that accelerate diagnosis without compromising clinical accuracy. Laboratory automation and digital reporting systems improve operational efficiency while supporting faster treatment decisions. These technological advancements reinforce the transition toward precision-based cardiovascular diagnostics.

Market Restraints

High capital investment required for advanced cardiac imaging systems limits adoption among smaller healthcare facilities and resource-constrained regions. Variability in access to specialized cardiology services and imaging expertise creates disparities in diagnostic availability across healthcare systems. Reimbursement limitations for advanced diagnostic procedures restrict broader utilization despite increasing clinical evidence supporting comprehensive heart failure assessment. Additionally, the complexity of integrating multiple diagnostic modalities into cohesive clinical workflows can present operational challenges.

Technology and Segment Insights

By Diagnostic Test

Natriuretic peptide testing (BNP and NT-proBNP) represents the largest diagnostic segment because these biomarkers remain the recommended standard for evaluating patients with suspected heart failure. Clinical guidelines continue supporting their routine use due to their ability to differentiate heart failure from non-cardiac causes of dyspnea and estimate disease severity. Cardiac troponin tests are increasingly utilized for risk stratification and to detect myocardial injury in heart failure patients. Echocardiography is the primary imaging modality for assessing cardiac structure and function, providing critical information on ejection fraction and valvular abnormalities. Electrocardiography (ECG) remains a fundamental screening tool. Cardiac magnetic resonance imaging (MRI) offers superior tissue characterization for complex cases. Computed tomography (CT) and chest X-ray provide complementary anatomical information. Point-of-care heart failure testing is gaining adoption because rapid biomarker assessment supports immediate clinical decision-making in emergency and outpatient settings.

By Technology

Immunoassays dominate the technology landscape because they provide highly sensitive and standardized quantification of natriuretic peptides and cardiac troponins. Clinical chemistry analyzers support broad laboratory testing capabilities. Molecular diagnostics are emerging for advanced risk assessment. Ultrasound imaging systems, including advanced echocardiography platforms, are essential for structural and functional assessment. AI-enabled diagnostic platforms are increasingly integrated to improve interpretation consistency and workflow efficiency.

By End User

Hospitals represent the largest end-user segment because they manage acute heart failure admissions, emergency cardiovascular care, and long-term disease monitoring. Healthcare institutions are expanding laboratory automation and advanced imaging capabilities to improve diagnostic efficiency and patient outcomes. Diagnostic laboratories are increasing biomarker testing capacity. Cardiology clinics are adopting integrated diagnostic pathways for outpatient management. Ambulatory care centers and academic research institutes contribute to the market through specialized services and clinical innovation.

Competitive and Strategic Outlook

The competitive landscape features major diagnostic and imaging companies with strong cardiovascular portfolios. F. Hoffmann-La Roche Ltd. maintains a leading position through its comprehensive cardiovascular biomarker portfolio, including Elecsys immunoassays for NT-proBNP and cardiac troponins, supported by automated cobas analyzers. Abbott Laboratories differentiates itself through a broad portfolio of cardiovascular biomarkers, automated immunoassay systems (Alinity and ARCHITECT), and point-of-care technologies. Siemens Healthineers AG integrates laboratory medicine, advanced imaging, and digital health technologies, including Atellica laboratory systems and advanced cardiac imaging platforms. Beckman Coulter, Inc. (Danaher Corporation) focuses on high-performance clinical chemistry and immunoassay systems for large-scale cardiovascular testing. bioMerieux SA leverages its in vitro diagnostics expertise for laboratory automation. QuidelOrtho Corporation combines immunodiagnostics with point-of-care and centralized testing capabilities. Fujirebio Holdings specializes in high-quality immunoassay development. Sysmex Corporation integrates laboratory diagnostics, automation, and digital healthcare solutions.
Strategic developments include increasing integration of AI with cardiac imaging and laboratory diagnostics, expansion of point-of-care testing, and development of integrated diagnostic pathways. Companies are forming collaborations with healthcare providers and research institutions to validate novel biomarkers and improve clinical adoption. Product launches focus on high-sensitivity assays, automated laboratory systems, and AI-enabled imaging software. Companies that successfully combine biomarker testing, advanced imaging, and digital health solutions into comprehensive diagnostic ecosystems are expected to strengthen their competitive positions.

Conclusion

The heart failure diagnostics market is poised for substantial growth, driven by the rising prevalence of cardiovascular disease and the shift toward integrated, biomarker-guided diagnostic pathways. The evolution from symptom-based evaluation toward comprehensive diagnostic strategies combining biomarkers, advanced imaging, and digital tools is reshaping clinical practice. Companies that successfully develop integrated diagnostic solutions with strong clinical evidence and global reach are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Heart Failure Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2031)
3.7 Heart Failure Classification
3.8 Disease Burden & Unmet Clinical Needs
3.9 Epidemiology & Prevalence Analysis
3.10 Diagnosed Patient Population Analysis
3.11 Diagnostic Testing Volume Analysis
3.12 Heart Failure Diagnostic Pathway

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Product Innovation
6.3 Biomarker Innovation
6.4 AI Integration in Heart Failure Diagnosis
6.5 Digital Health Integration
6.6 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Heart Failure Diagnostics Market Landscape Analysis

8.1 Analysis by Diagnostic Modality
8.2 Analysis by Biomarker
8.3 Analysis by Technology Platform
8.4 Analysis by Clinical Application
8.5 Analysis by End User

9. Heart Failure Diagnostics Market Segment Analysis (2021-2031)

9.1 By Diagnostic Test
- 9.1.1 Natriuretic Peptide Tests (BNP & NT-proBNP)
- 9.1.2 Cardiac Troponin Tests
- 9.1.3 Echocardiography
- 9.1.4 Electrocardiography (ECG)
- 9.1.5 Cardiac Magnetic Resonance Imaging (Cardiac MRI)
- 9.1.6 Computed Tomography (CT)
- 9.1.7 Chest X-ray
- 9.1.8 Point-of-Care Heart Failure Testing
9.2 By Technology
- 9.2.1 Immunoassays
- 9.2.2 Clinical Chemistry Analyzers
- 9.2.3 Molecular Diagnostics
- 9.2.4 Ultrasound Imaging Systems
- 9.2.5 AI-enabled Diagnostic Platforms
9.3 By End User
- 9.3.1 Hospitals
- 9.3.2 Diagnostic Laboratories
- 9.3.3 Cardiology Clinics
- 9.3.4 Ambulatory Care Centers
- 9.3.5 Academic & Research Institutes